Notícias FarmaMondo

FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines has been appointed by EUSA Pharma to extend its current exclusive distribution of Qarziba®

FarmaMondo has been appointed to exclusively manage the access of Carmustine Obvius to Italian healthcare providers looking to fulfill unmet medical needs of patients with

FarmaMondo SA announces it has established FarmaMondo Mexico, a fully owned subsidiary of FarmaMondo SA. The Mexican affiliate will upgrade the group’s capabilities in providing

FarmaMondo Nordics Aps, a fully owned subsidiary of FarmaMondo SA, has received a GMP license from the Danish Medicines Agency. With this license in place,

FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines, will exclusively distribute Spectrila® via a Managed Access Program for targeted Healthcare Providers in

Merck’s Keytruda (Pembrolizumab) showed better results than chemotherapy at improving overall survival among first-line patients with non-small cell lung cancer in a trial whose results

AstraZeneca’s Tagrisso has been approved by FDA as a first-line treatment for patients with metastatic non-small-cell lung cancer characterized by epidermal growth factor receptor (EGFR)

FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines, has been appointed by Amomed Pharma to exclusively distribute Empressin® via a Managed Access